title: Calcium channel blocker use and risk of Parkinson's disease.
abstract: We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.
authors.affiliation: Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ksimon@hsph.harvard.edu
authors.forename: Kelly Claire
authors.initials: KC
authors.lastname: Simon
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.forename: Honglei
authors.initials: H
authors.lastname: Chen
authors.forename: Michael A
authors.initials: MA
authors.lastname: Schwarzschild
authors.forename: Alberto
authors.initials: A
authors.lastname: Ascherio
mesh_terms: D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009726:Nurses; D010300:Parkinson Disease / Q000209:etiology*; D016016:Proportional Hazards Models; D012306:Risk
chemical_list: D002121:Calcium Channel Blockers